JP2023531968A - 抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法 - Google Patents

抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法 Download PDF

Info

Publication number
JP2023531968A
JP2023531968A JP2022579724A JP2022579724A JP2023531968A JP 2023531968 A JP2023531968 A JP 2023531968A JP 2022579724 A JP2022579724 A JP 2022579724A JP 2022579724 A JP2022579724 A JP 2022579724A JP 2023531968 A JP2023531968 A JP 2023531968A
Authority
JP
Japan
Prior art keywords
bet
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579724A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022006305A5 (https=
JP2023531968A5 (https=
Inventor
アマンダ アタナシオ，
ゲイリー ハーマン，
ミーガン ピー． オブライエン，
ジェイミー エム． オレンゴ，
ロラ パーリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023531968A publication Critical patent/JP2023531968A/ja
Publication of JPWO2022006305A5 publication Critical patent/JPWO2022006305A5/ja
Publication of JP2023531968A5 publication Critical patent/JP2023531968A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2022579724A 2020-07-01 2021-06-30 抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法 Pending JP2023531968A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US63/047,126 2020-07-01
US202063129253P 2020-12-22 2020-12-22
US63/129,253 2020-12-22
PCT/US2021/039945 WO2022006305A1 (en) 2020-07-01 2021-06-30 Methods of treating allergy using anti-bet v 1 antibodies

Publications (3)

Publication Number Publication Date
JP2023531968A true JP2023531968A (ja) 2023-07-26
JPWO2022006305A5 JPWO2022006305A5 (https=) 2024-07-08
JP2023531968A5 JP2023531968A5 (https=) 2024-07-08

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579724A Pending JP2023531968A (ja) 2020-07-01 2021-06-30 抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法

Country Status (12)

Country Link
US (2) US11897945B2 (https=)
EP (1) EP4175986A1 (https=)
JP (1) JP2023531968A (https=)
KR (1) KR20230030573A (https=)
CN (1) CN115698059A (https=)
AU (1) AU2021300129A1 (https=)
BR (1) BR112022026279A2 (https=)
CA (1) CA3177918A1 (https=)
CL (1) CL2022003744A1 (https=)
IL (1) IL299207A (https=)
MX (1) MX2022015677A (https=)
WO (1) WO2022006305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298034B2 (en) * 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222854A1 (en) * 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222854A1 (en) * 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATANASIO, A. ET AL.: "Targeting birch allergy with monoclonal IgG antibodies that bind allergen and prevent IgE effector c", ALLERGY, vol. Vol.74，Suppl.106, JPN6025027527, 2019, pages 114, ISSN: 0005745944 *
FRANKLIN, M. C. ET AL.: "Three specific monoclonal antibodies bound to the major birch allergen Bet V 1 are sufficient to blo", ALLERGY, vol. Vol.74，Suppl.106, JPN6025027528, 2019, pages 709 - 710, ISSN: 0005745945 *
内藤 健晴: "スギ花粉症に対する初期治療(季節前投与)の臨床効果", 鼻アレルギーフロンティア, vol. 第4巻, 第1号, JPN6025049885, 2004, pages 70 - 75, ISSN: 0005745947 *
渡邉 昭仁, 川堀 眞一: "ダレンのシラカンバ花粉症に対する治療効果 季節前投与の有用性", 耳鼻咽喉科臨床, vol. 第93巻, 第5号, JPN6025049884, 2000, pages 419 - 424, ISSN: 0005745946 *

Also Published As

Publication number Publication date
CL2022003744A1 (es) 2023-06-02
US20240209074A1 (en) 2024-06-27
US12583914B2 (en) 2026-03-24
IL299207A (en) 2023-02-01
AU2021300129A1 (en) 2022-12-08
MX2022015677A (es) 2023-02-22
CA3177918A1 (en) 2022-01-06
EP4175986A1 (en) 2023-05-10
WO2022006305A1 (en) 2022-01-06
BR112022026279A2 (pt) 2023-02-14
US20220002394A1 (en) 2022-01-06
CN115698059A (zh) 2023-02-03
KR20230030573A (ko) 2023-03-06
US11897945B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
JP7458453B2 (ja) Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法
US11504426B2 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US12583914B2 (en) Methods of treating allergy using anti-bet v 1 antibodies
IL265104B2 (en) Methods for preventing or treating allergy by administering an agonist for IL-4R
US20250263471A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
JP2024539148A (ja) Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法
US20240092882A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
RU2833729C2 (ru) Способы лечения аллергии и усиления аллерген-специфической иммунотерапии путем введения антагониста il-4r
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r
WO2022089595A1 (en) Biomarkers for ige-mediated diseases
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
AU2017321682B2 (en) Methods for preventing or treating allergy by administering an IL-4R antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212